Client News

Home/Client News

ASIT biotech Mode of Action Study of gp-ASIT+™ for Grass Pollen Allergy Published in The Journal of Allergy and Clinical Immunology (JACI)

BRUSSELS, Belgium, Oct. 17, 2019 (GLOBE NEWSWIRE) — ASIT biotech (Euronext:ASIT – BE0974289218), a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, today announced the publication of a mechanistic (mode of action) study  of gp-ASIT+™, its lead product candidate in Phase III for grass pollen allergy, in the Journal […]

By | 2019-10-17T16:39:25+00:00 October 17th, 2019|Client News|Comments Off on ASIT biotech Mode of Action Study of gp-ASIT+™ for Grass Pollen Allergy Published in The Journal of Allergy and Clinical Immunology (JACI)

Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics’ Board of Directors.

By | 2019-10-17T16:38:19+00:00 October 17th, 2019|Client News|Comments Off on Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin’s Vice President of Pre-Clinical Development, provided a presentation on Palatin’s oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Symposium on Peptide Therapeutics in

By | 2019-10-17T16:37:25+00:00 October 17th, 2019|Client News|Comments Off on Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the publication […]

By | 2019-10-17T16:36:22+00:00 October 17th, 2019|Client News|Comments Off on ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were […]

By | 2019-10-17T16:35:29+00:00 October 17th, 2019|Client News|Comments Off on Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, Israel, Oct. 17, 2019 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced positive 12-month on-treatment data from the first 16 out of the 22 […]

By | 2019-10-17T16:34:22+00:00 October 17th, 2019|Client News|Comments Off on Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the upcoming 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, being held from October 26 – 30, 2019 […]

By | 2019-10-17T16:33:07+00:00 October 17th, 2019|Client News|Comments Off on Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

Genocea to Host Third Quarter 2019 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference call and live audio webcast on Thursday, October 24that 8:30 a.m. EDT.

By | 2019-10-17T16:27:46+00:00 October 17th, 2019|Client News|Comments Off on Genocea to Host Third Quarter 2019 Corporate Update Conference Call & Webcast

NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies

PITTSBURGH, Oct. 17, 2019 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,370,415 covering the Company’s proprietary DNA and RNA binding technology. This foundational patent enables […]

By | 2019-10-17T16:26:05+00:00 October 17th, 2019|Client News|Comments Off on NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies

Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients

HOPKINTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and […]

By | 2019-10-17T16:25:02+00:00 October 17th, 2019|Client News|Comments Off on Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients

Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

NEW YORK, Oct. 17, 2019 /PRNewswire/ — Relmada Therapeutics Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today that the Relmada team will ring the NASDAQ stock market opening bell tomorrow, Friday, October 18, 2019, at 9:30 AM ET, to commemorate […]

By | 2019-10-17T16:24:13+00:00 October 17th, 2019|Client News|Comments Off on Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

TORONTO, Oct. 17, 2019 /PRNewswire/ — Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO®Spermatogenesis Study as part of the “Late Breaking” Abstract Session at the 75th Annual American Society for Reproductive Medicine (ASRM) Scientific Conference in Philadelphia, PA.Yesterday’s presentation was one of only six abstracts […]

By | 2019-10-17T16:23:20+00:00 October 17th, 2019|Client News|Comments Off on New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019/PRNewswire/ — Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) […]

By | 2019-10-17T16:21:37+00:00 October 17th, 2019|Client News|Comments Off on Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Cystic Fibrosis Foundation (CFF) Data Safety Monitoring Board (DSMB) has completed  its review of the Company’s final results of the Phase 2 OPTION […]

By | 2019-10-17T16:20:27+00:00 October 17th, 2019|Client News|Comments Off on AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

DURECT to Present at Two Upcoming NASH Investor Conferences

CUPERTINO, Calif., Oct. 17, 2019 /PRNewswire/ — DURECT Corporation (DRRX) announced today that it will be presenting at two upcoming investor conferences focused on non-alcoholic steatohepatitis (NASH): the H.C. Wainwright 3rd Annual NASH Investor Conference, to be held in New York City on Monday, October 21, 2019 and […]

By | 2019-10-17T16:19:18+00:00 October 17th, 2019|Client News|Comments Off on DURECT to Present at Two Upcoming NASH Investor Conferences

Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia

BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the company has withdrawn its submission to the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for NUZYRA® (omadacycline).

By | 2019-10-17T16:17:28+00:00 October 17th, 2019|Client News|Comments Off on Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia

TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its fiscal second quarter ended September 30, 2019. During the quarter, TYME released new clinical data at major international medical meetings on its lead […]

By | 2019-10-17T16:16:27+00:00 October 17th, 2019|Client News|Comments Off on TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019

ALAMEDA, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the […]

By | 2019-10-16T17:26:19+00:00 October 16th, 2019|Client News|Comments Off on OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019

Top Researchers to Present Discoveries Made Possible by Bionano’s Saphyr System for Genome Imaging Technology at the ASHG 2019 Annual Meeting

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO) today announced that disease researchers using Bionano’s Saphyr system for whole genome imaging will present their results at the American Society of Human Genetics (ASHG) Annual Meeting, between October 15-19 in Austin, Texas.

By | 2019-10-16T17:24:52+00:00 October 16th, 2019|Client News|Comments Off on Top Researchers to Present Discoveries Made Possible by Bionano’s Saphyr System for Genome Imaging Technology at the ASHG 2019 Annual Meeting

miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

BOULDER, Colo., Oct. 16, 2019 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased […]

By | 2019-10-16T17:23:39+00:00 October 16th, 2019|Client News|Comments Off on miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data on Vyleesi™ (bremelanotide injection) for hypoactive sexual desire disorder (HSDD) will be presented at the 13th European Society of Gynecology Conference in […]

By | 2019-10-16T17:22:29+00:00 October 16th, 2019|Client News|Comments Off on Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director

MARINA DEL REY, Calif., Oct. 16, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the appointment of Heather Dale Jones, M.D. as its first Medical Director, further strengthening Armata’s clinical team as the company prepares […]

By | 2019-10-16T17:21:05+00:00 October 16th, 2019|Client News|Comments Off on Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director

Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™

GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the successful completion of a 30-day rat […]

By | 2019-10-16T17:20:10+00:00 October 16th, 2019|Client News|Comments Off on Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™

RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment […]

By | 2019-10-16T17:19:03+00:00 October 16th, 2019|Client News|Comments Off on RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month

Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced that leading organizations, including PerkinElmer Genomics and the University of Iowa, have adopted Saphyr for use […]

By | 2019-10-16T17:16:24+00:00 October 16th, 2019|Client News|Comments Off on Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing

CorMedix Completes Successful CMC Interaction with the FDA

BERKELEY HEIGHTS, N.J., Oct. 16, 2019 (GLOBE NEWSWIRE) — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its interaction with the FDA related to the chemistry, manufacturing and controls (CMC) package that […]

By | 2019-10-16T17:15:06+00:00 October 16th, 2019|Client News|Comments Off on CorMedix Completes Successful CMC Interaction with the FDA

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

WATERTOWN, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) — Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the first patient has completed the initial cycle of treatment in the Company’s first clinical trial evaluating ALRN-6924 as a myelopreservation agent in patients with p53-mutant small-cell lung cancers […]

By | 2019-10-16T17:05:24+00:00 October 16th, 2019|Client News|Comments Off on Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

NEW YORK, Oct. 15, 2019 /PRNewswire/ — Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today reported top-line data from REL-1017-202, a double-blind, placebo-controlled Phase 2 clinical study evaluating the safety, tolerability and efficacy of two doses of REL-1017 (dextromethadone), 25 […]

By | 2019-10-15T15:43:27+00:00 October 15th, 2019|Client News|Comments Off on Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

HTG Announces the Launch of its New Autoimmune Profiling Assay

TUCSON, Ariz., Oct. 15, 2019 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form […]

By | 2019-10-15T15:42:17+00:00 October 15th, 2019|Client News|Comments Off on HTG Announces the Launch of its New Autoimmune Profiling Assay

Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center

CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Houston Oncology Summit at the University of Texas MD […]

By | 2019-10-15T15:40:44+00:00 October 15th, 2019|Client News|Comments Off on Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center